Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database

DOI Web Site Web Site PubMed 参考文献20件
  • Yamashita Shinsuke
    Graduate School of Life Science, Hokkaido University Department of Pharmacy, Hokkaido University Hospital
  • Imai Shungo
    Faculty of Pharmaceutical Sciences, Hokkaido University
  • Momo Kenji
    Department of Hospital Pharmaceutics, School of Pharmacy, Showa University
  • Kashiwagi Hitoshi
    Faculty of Pharmaceutical Sciences, Hokkaido University
  • Sato Yuki
    Faculty of Pharmaceutical Sciences, Hokkaido University
  • Sugawara Mitsuru
    Department of Pharmacy, Hokkaido University Hospital Faculty of Pharmaceutical Sciences, Hokkaido University Global Station for Biosurfaces and Drug Discovery, Hokkaido University
  • Takekuma Yoh
    Department of Pharmacy, Hokkaido University Hospital

この論文をさがす

抄録

<p>Olanzapine is effective for schizophrenia management; however, it is contraindicated in diabetes patients. In addition, olanzapine is useful for treating nausea and vomiting, such as in the case of chemotherapy-induced nausea and vomiting (CINV). Therefore, we hypothesized that the contraindicated prescription of olanzapine likely occurs among cancer patients with diabetes, especially by non-psychiatric physicians. Hence, we conducted a nationwide survey to elucidate the situation of such contraindicated prescriptions and the associated risk factors. We extracted the data of patients who were newly prescribed olanzapine between April 2015 and March 2017 from the health insurance claims database developed by JMDC, Inc., Tokyo. The patients who were prescribed contraindicated olanzapine were defined as those who were prescribed olanzapine after a diagnosis of diabetes and diabetes drug prescription. In all, the data of 7181 patients were analyzed. We evaluated the proportion of diabetes patients who were prescribed contraindicated olanzapine from among those who were prescribed olanzapine. Furthermore, we investigated the background of patients who were prescribed olanzapine for information such as olanzapine prescribers and history of cancer chemotherapy. In all, 100 diabetes patients (1.39%) were prescribed olanzapine. In these patients, the frequency of olanzapine prescription was higher by non-psychiatry/neurology physicians than by psychiatry/neurology physicians (3.25 and 0.85%, respectively). Additionally, all olanzapine prescriptions in cancer chemotherapy-treated diabetes patients were issued by non-psychiatry/neurology physicians. Thus, our study revealed there were diabetes patients who were prescribed olanzapine. Additionally, olanzapine for CINV management was more likely to be a contraindicated prescription.</p>

収録刊行物

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ